Tore K. Kvien
Professor Emeritus
https://orcid.org/0000-0002-8441-3093
https://orcid.org/0000-0002-8441-3093
Education
- Can. with, University of Oslo
- PhD, Faculty of Medicine, University of Oslo (1986)
Score
- Head of Department at the Rheumatology Department, Diakonhjemmet Hospital from 1994 - 2019
- Professor emeritus, University of Oslo
Field of interest
- Musculoskeletal diseases
- Register studies
- Randomized controlled trials
Other
- Appointed a knight of the 1st class of the Order of St. Olav for his efforts in rheumatology (2019)
- Former President of the European Society of Rheumatology
- Former editor of Annals of Rheumatic Diseases
Telephone
visiting address
Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
WP1 - Optimized medical interventions
ARCTIC
Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up
Project Manager:
Espen A. HaavardsholmPublications
Publications taken from the National Science Archive (NVA):
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial
Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
The Lancet Rheumatology
2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Gehin, Kristin Reine Hammersbøen, David Warren, Rolf Klaasen, Joseph Sexton
The Lancet Rheumatology
2024
Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: results from an international collaboration
Celina K. Gehringer, Glen P. Martin, Kimme L. Hyrich, Suzanne MM Verstappen, Joseph Sexton, Eirik Kristianslund
Journal of Clinical Epidemiology
2024
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
Kim Lauper, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Jacques-Eric Gottenberg
Joint Bone Spine
2024
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen
RMD Open
2024
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)
Romain Aymon, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Diederik De Cock
Annals of the Rheumatic Diseases
2023
Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg
Annals of the Rheumatic Diseases
2023
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Brigitte Michelsen, Mikkel Østergaard, Michael John Nissen, Adrian Ciurea, Burkhard Möller, Lykke Midtbøll Ørnbjerg
The Lancet Regional Health - Europe
2023
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31,846 patients with rheumatoid arthritis in 19 registers from the JAK-pot' collaboration
Kim Lauper, Michele Ludici, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu
Annals of the Rheumatic Diseases
2022
Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data
Vibeke Norvang, Espen A. Haavardsholm, Sara K. Tedeschi, Houchen Lyu, Joseph Sexton, Maria Dahl Mjaavatten
BMC Medical Research Methodology
2022
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
Hilde Berner Hammer, Silvia Christin Hellerud Rollefstad, Anne Grete Semb, Gro Elisabeth Jensen, Lars Fridtjof Karoliussen, L Terslev
RMD Open
2022
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, Anne G. Loft, Michael J. Nissen, Florenzo Iannone
Arthritis care & research
2022
Study protocol for the follow-up examination of the Nor-Hand study: A hospital-based observational cohort study exploring pain and biomarkers in people with hand osteoarthritis
Marthe Gløersen, Pernille Steen Pettersen, Øystein Gunnar Maugesten, Elisabeth Mulrooney, Alexander Mathiessen, Heidi Gammelsrud
Osteoarthritis and Cartilage Open
2021
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Reine Hammersbøen
Journal of the American Medical Association (JAMA)
2021
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
Mike Oliver Becker, Rucsandra Dobrota, Alexandru Garaiman, Rudolf Debelak, Kim Fligelstone, Ann Tyrrell Kennedy
Annals of the Rheumatic Diseases
2021
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
Ana-Maria Orbai, Dafna D. Gladman, Hitoshi Goto, Julie A. Birt, Amanda M. Gellett, Chen-Yen Lin
Clinical and Experimental Rheumatology
2021
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Johanna Elin Gehin, David Warren, Silje Watterdal Syversen, Elisabeth Lie, Joseph Sexton, Liz Paucar Loli
Scandinavian Journal of Rheumatology
2021
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Mielnik Pawel, Gunnstein Bakland, Liz Paucar Loli, Joseph Sexton
Annals of the Rheumatic Diseases
2021
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target
Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tove Borgen, Espen A. Haavardsholm, Tore Kristian Kvien
RMD Open
2021
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
Journal of the American Medical Association (JAMA)
2021
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
Ulf Gunnar Sundin, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Lena Kristine Bugge Nordberg, Hilde Berner Hammer
RMD Open
2021
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen
Journal of the American Medical Association (JAMA)
2021
Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: A cross-sectional study of 671 patients
Cátia Duarte, Eduardo José Ferreira Santos, Ricardo Jorge de Oliveira Ferreira, Tore Kristian Kvien, Maxime Dougados, Maarten de Wit
RMD Open
2021
Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort
Øystein Gunnar Maugesten, Alexander Mathiessen, Hilde Berner Hammer, Sigrid Valen Hestetun, Tore Kristian Kvien, Till Uhlig
Arthritis Research & Therapy
2020
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
Brigitte Michelsen, Ulf Lindström, Catalin Codreanu, Adrian Ciurea, Jakub Zavada, Anne Gitte Loft
RMD Open
2020
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin
Trials
2020
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
Laura Coates, Peter Nash, Tore Kristian Kvien, Laure Gossec, Philip J. Mease, Lawrence Rasouliyan
Seminars in Arthritis & Rheumatism
2020